Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients by Oliveira, A. L. et al.
ORIGINAL ARTICLE
Epidemiology of bacteremia and factors associated with multi-drug-
resistant gram-negative bacteremia in hematopoietic stem cell transplant
recipients
AL Oliveira1, M de Souza2, VMH Carvalho-Dias3, MA Ruiz4,14, L Silla5, P Yurie Tanaka6, BP Simo˜es7,
P Trabasso8, A Seber9, CJ Lotﬁ10, MA Zanichelli11, VR Araujo12, C Godoy13, A Maiolino1,
P Urakawa2, CA Cunha3, CA de Souza8, R Pasquini3 and M Nucci1
1Hospital Universita´rio, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; 2Hospital Amaral Carvalho, Jau´, Brazil;
3Hospital das Clı´nicas, Universidade Federal do Parana´, Curitiba, Brazil; 4Hospital de Base, Sa˜o Jose´ do Rio Preto, Brazil; 5Hospital
das Clı´nicas, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil; 6Irmandade da Santa Casa de Miserico´rdia de Sa˜o
Paulo, Sa˜o Paulo, Brazil; 7Hospital das Clı´nicas, Universidade de Sa˜o Paulo, Ribeira˜o Preto, Brazil; 8Hospital das Clı´nicas,
Universidade Estadual de Campinas, Campinas, Brazil; 9Instituto de Oncologia Pedia´trica – GRAAC – UNIFESP, Sa˜o Paulo, Brazil;
10Hospital AC Camargo, Sa˜o Paulo, Brazil; 11Hospital Brigadeiro, Sa˜o Paulo, Brazil; 12Centro de Pesquisas Oncolo´gicas,
Floriano´polis, Brazil and 13Hospital Arau´jo Jorge, Goiaˆnia, Brazil
The incidence of Gram-negative bacteremia has increased
in hematopoietic stem cell transplant (HSCT) recipients.
We prospectively collected data from 13 Brazilian HSCT
centers to characterize the epidemiology of bacteremia
occurring early post transplant, and to identify factors
associated with infection due to multi-drug-resistant
(MDR) Gram-negative isolates. MDR was deﬁned as an
isolate with resistance to at least two of the following:
third- or fourth-generation cephalosporins, carbapenems
or piperacillin-tazobactam. Among 411 HSCT, fever
occurred in 333, and 91 developed bacteremia (118
isolates): 47% owing to Gram-positive, 37% owing to
Gram-negative, and 16% caused by Gram-positive and
Gram-negative bacteria. Pseudomonas aeruginosa (22%),
Klebsiella pneumoniae (19%) and Escherichia coli (17%)
accounted for the majority of Gram-negative isolates, and
37% were MDR. These isolates were recovered from 20
patients, representing 5% of all 411 HSCT and 22% of
the episodes with bacteremia. By multivariate analysis,
treatment with third-generation cephalosporins (odds ratio
(OR) 10.65, 95% conﬁdence interval (CI) 3.75–30.27)
and being at one of the hospitals (OR 9.47, 95% CI
2.60–34.40) were associated with infection due to MDR
Gram-negative isolates. These ﬁndings may have impor-
tant clinical implications in the decision of giving
prophylaxis and selecting the empiric antibiotic regimen.
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Introduction
Bacteremia remains an important cause of infection among
hematopoietic stem cell transplant (HSCT) recipients,
occurring in up to 30% of febrile neutropenic episodes
during the early post-transplant period.1 Over the past
decade, Gram-positive bacteria accounted for the large
majority of pathogens causing bacteremia during neutro-
penia.2,3 However, recent studies have reported a re-
emergence of Gram-negative bacteria in neutropenic cancer
patients. Haupt et al.4 observed a 3.4% increase per year in
Gram-negative bacteremia among children treated for solid
tumors from 1985 to 1996. Collin et al.1 reported a decrease
in the ratio of Gram-positive/Gram-negative, from 2.7 to
1.3 in bacteremic HSCT recipients. A recent trial conducted
by the EORTC-IATG showed an increase of Gram-
negative bacteremia in neutropenic patients, from 6.5 to
12% (Po0.001).5 The reasons for these epidemiologic
changes are not clear.
In recent years, a notable increase in antibiotic resistance
among Gram-negative bacteria has been reported, espe-
cially in critically ill patients.6 These infections are
associated with increased morbidity, mortality, and costs.7,8
In our institution, we observed that 4.5% of 245
bacteremias occurring during neutropenia in HSCT reci-
pients were caused by multi-drug-resistant (MDR) Gram-
negative bacteria, representing an increase from 1.7 cases
per 1000 days of neutropenia between 1994 and 2002 to 8.6
cases per 1000 days of neutropenia in 2003.9 Furthermore,
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MDR Gram-negative bacteremia was associated with
a seven-fold increase in the risk of death by multivari-
ate analysis. While epidemiologic studies conducted in
Brazilian institutions suggest that infection owing to
MDR Gram-negative bacteria is a great problem,10–12
the magnitude of this problem in HSCT recipients is
not known.
The purpose of this study was to evaluate the epidemio-
logy of bacteremia occurring during the period of
neutropenia of Brazilian HSCT recipients, with a special
emphasis on the prevalence, susceptibility proﬁle
and factors associated with MDR Gram-negative
bacteremia.
Patients and methods
The study was conducted between 1 March and 30
November 2004 in 13 Brazilian HSCT centers located in
10 cities of the south, southeast and central regions of
Brazil. All centers have an active program of HSCT
(autologous and/or allogeneic), an automated blood culture
system (BACTECR or BacT/ALERTR), and follow stan-
dard procedures for species identiﬁcation and susceptibility
tests of bacteria.13 All HSCT recipients who developed
neutropenia after the conditioning regimen were included
in this cohort. The patients were followed from day zero
until neutrophil engraftment or death. A standardized case
report form was prospectively completed and sent electro-
nically to the data management center. The case report
form contained the following information: demographics,
underlying disease and its status at the time of transplant
(active disease vs in complete remission), type of transplant
(autologous, allogeneic with myeloablative conditioning
regimen, non-myeloablative, HLA-mismatched, unrelated),
source of stem cells (peripheral blood, bone marrow, cord
blood), conditioning regimen, antimicrobial prophylaxis,
fever, empiric antibiotic regimen, classiﬁcation of the febrile
episode, documentation of infection, and if the patient
developed bacteremia, species identiﬁcation and suscepti-
bility proﬁle of the etiologic agent(s) of bacteremia. In
addition, information on the total duration of neutropenia
and the outcome were recorded.
The protocol for the management of neutropenia
(including antimicrobial prophylaxis and therapy of febrile
neutropenia) was followed according to standards of each
center. Neutropenia was deﬁned as a neutrophil count
o500 cells 109/l, and fever as an axillary temperature
X37.81C. The febrile episodes were classiﬁed according to
deﬁnitions of the Immunocompromised Host Society as
fever of unknown origin (FUO), bacteremia, microbiolo-
gically documented infection without bacteremia, and
clinically documented infection.14 Breakthrough bactere-
mia was deﬁned as an episode of bacteremia occurring
424 h after the initiation of empiric antibiotic therapy. A
Gram-negative isolate that exhibited resistance to at least
two antibiotics used in empirical therapy (third and fourth-
generation cephalosporins, carbapenems or piperacillin-
tazobactam) was deﬁned as MDR. Neutrophil engraftment
was deﬁned when three consecutive neutrophil counts were
4500 106/l.
Data were entered by a web-based case report form,
using the SPSS Enterprise Server 3.0 and SPSS Data Entry
Builder 3.03 (SPSS Inc., Chicago, IL, USA). Categorical
data were analyzed using w2 or Fisher’s exact tests, as
appropriate, and continuous variables were compared
using the Wilcoxon test. We performed univariate and
multivariate analyses of factors associated with the devel-
opment of fever and bacteremia due to MDR Gram-
negative bacteria by comparing patients with and without
these features. Variables signiﬁcant at Po0.1 by univariate
analysis were included in a multivariate model (backward
and forward). Data were analyzed using the SPSS 11.0.1
software (SPSS Inc., Chicago, IL, USA).
Results
Patients’ demographics and antimicrobial usage
During the study period, 411 HSCT (225 allogeneic and
186 autologous) were performed in the 13 institutions. The
median number of HSCT per center was 16 (range 9–114).
Characteristics of the HSCT are shown in Table 1. Among
allogeneic HSCT, the most frequent underlying diseases
were chronic myeloid leukemia (CML – 75 patients, 33%)
and acute myeloid leukemia (AML – 44 patients, 20%).
Among autologous HSCT, multiple myeloma (65 patients,
35%), Hodgkin’s disease and non-Hodgkin’s lymphoma
(40 patients each, 21%) were the most frequent underlying
diseases. The stem cell source was the peripheral blood in
252 (61%), bone marrow in 142 (35%) and cord blood in
17 (4%). The median age of patients was 32 (range 1–66
years) and 230 patients were men. Fifteen patients (seven
autologous and eight allogeneic) underwent a second
transplant.
Antibacterial prophylaxis was given to 138 patients
(34%), mostly betalactam agents (51%) and quinolones
(38%). Antifungal prophylaxis was given to 87% of
patients, and ﬂuconazole was the most frequently pre-
scribed drug (83%). Fever occurred in 333 HSCT (81%).
Patients receiving quinolone prophylaxis (odds ratio (OR)
0.15, 95% conﬁdence interval (CI) 0.08–0.31, Po0.001)
and recipients of non-myeloablative HSCT (OR 0.13,
Table 1 Characteristics of 411 hematopoietic stem cell transplants
Characteristic N
Number of HSCT per center, median (range) 16 (9–114)
Median age (range) 32 (1–66)
Gender, male:female 230:181
Type of HSCT, n (%)
Autologous 186 (45)
Peripheral blood/bone marrow 168/18
Allogeneic 225 (55)
Related donor, HLA-compatible 182 (81)
Peripheral blood/bone marrow/cord blood 71/110/1
Allogeneic, related donor, non-myeloablative 13 (6)
Peripheral blood/bone marrow 11/2
Allogeneic, unrelated donor 26 (11)
Peripheral blood/bone marrow/cord blood 1/9/16
Allogeneic, related donor, mismatched 4 (2)
Peripheral blood/bone marrow 3/1
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95% CI 0.04–0.44, P¼ 0.001) were less likely to develop
fever during neutropenia by multivariate analysis. Empiri-
cal antibiotic therapy was given as follows: monotherapy
with a betalactam in 52%, betalactam plus vancomycin in
27%, betalactam plus an aminoglycoside in 11%, betalac-
tam plus an aminoglycoside plus vancomycin in 4% and
other regimens in 6%. The most commonly used betalac-
tams were cefepime (74%) and ceftazidime (12%). A
carbapenem was used in only 4% of febrile episodes.
Empirical antifungal therapy was given in 28% of febrile
episodes (deoxycholate amphotericin B in 75%, ﬂuconazole
in 20%), ranging between 7 and 87% among the different
institutions.
Etiology of infection and susceptibility pattern of bacterial
isolates
The classiﬁcation of the 333 febrile episodes was FUO in
163 episodes (49%), bacteremia in 91 (27%), clinically
documented infection in 58 (18%), microbiologically
documented infection without bacteremia in 10 (3%) and
non-infectious fever in 11 (3%). A total of 118 bacterial
isolates were recovered from the 91 febrile episodes with
bacteremia. Most bacteremias were due to a single agent
(69 episodes), either Gram-positive (41 episodes) or Gram-
negative (28 episodes), whereas 22 episodes had more than
one species isolated: two isolates in each of 18 bacteremic
episodes, three isolates in each of three bacteremic episodes,
and four isolates in one bacteremic episode. Forty-three
episodes (47%), were caused by Gram-positive bacteria, 34
(37%) were caused by Gram-negative bacteria, and 14
(16%) were caused by both Gram-positive and Gram-
negative bacteria. Breakthrough bacteremia occurred in 23
of the 91 episodes with bacteremia (25%), and involved
Gram-negative bacteria in the majority of cases (15
episodes).
As shown in Table 2, 59 Gram-positive and 59 Gram-
negative isolates were recovered from blood cultures.
Among Gram-negative bacteria, Pseudomonas aeruginosa
(22%), Klebsiella pneumoniae (19%) and Escherichia coli
(17%) accounted for the majority of isolates. Enterobacter
species and Acinetobacter species accounted for 12 and
10% of Gram-negative bloodstream isolates, respectively.
Twenty-two of the 59 Gram-negative isolates (37%) were
MDR. These isolates were recovered from 20 patients,
representing 5% of all 411 HSCT, 6% of the 333 febrile
neutropenic episodes, and 22% of the episodes with
bacteremia. The episodes of MDR Gram-negative bacter-
emia were distributed through 10 of the 13 centers, with a
prevalence varying between 0 and 18%. The MDR Gram-
negative isolates were: K. pneumoniae (6), P. aeruginosa (5),
Enterobacter spp (3), E. coli (2), Burkholderia cepacia (2),
Stenotrophomonas malthophilia (2), Acinetobacter spp (1)
and Citrobacter freundii (1).
As shown in Table 3, all MDR Gram-negative isolates
were resistant to ceftazidime. E. coli and most K.
pneumoniae isolates (four of ﬁve) remained susceptible to
imipenem, whereas most P. aeruginosa isolates (four of ﬁve)
were resistant to this antibiotic. Resistance to ciproﬂoxacin
was observed in ﬁve of six MDR K. pneumoniae and four of
ﬁve MDR P. aeruginosa. A high rate of resistance to
amikacin was also observed. There was no apparent cluster
of a speciﬁc MDR phenotype in any of the 13 institutions.
Risk factors for MDR-Gram-negative
Patients who received third generation cephalosporins
either as prophylaxis or empirical therapy were more likely
to develop infection due to MDR Gram-negative isolates
(20 vs 3%, Po0.001), as were patients admitted to two of
the 13 hospitals (18 vs 4%, P¼ 0.02, and 15 vs 4%,
P¼ 0.02, respectively). By contrast, patients admitted to
another center were less likely to have infection due to
MDR Gram-negative isolates (1 vs 6%, P¼ 0.02). By
multivariate analysis, receipt of third generation cephalos-
porins (OR 10.65, 95% CI 3.75–30.27) and being at one of
the hospitals (OR 9.47, 95% CI 2.60–34.40) were associated
with infection due to MDR Gram-negative isolates
(Table 4). Interestingly, no patient admitted to this hospital
had received third-generation cephalosporins.
We ran the same analysis of potential risk factors for
infection due to MDR Gram-negative isolates excluding
the 78 HSCT recipients who did not develop fever during
neutropenia. Again, receipt of third-generation cephalos-
porins (20 vs 4%, P¼ 0.001), and being at those two
hospitals (33 vs 4%, P¼ 0.001, and 21 vs 5%, P¼ 0.01,
respectively) were associated with infection due to MDR
Gram-negative isolates. In addition, there was a trend for
an association between use of quinolone as prophylaxis and
MDR Gram-negative bacteremia (14 vs 5%, P¼ 0.07).
However, by multivariate analysis, receipt of third-genera-
tion cephalosporins (OR 9.69, 95% CI 3.29–28.56) and
being at the same hospital as for the previous analysis
Table 2 Etiologic agents in 91 febrile episodes with bacteremia
Agent Time of positive blood culture
from the start of empiric
antibiotic therapy
Total
n (%)
First day,
n
Breakthrough,
n
Gram-positive 50 9 59
Coagulase-negative
staphylococci
27 2 29 (50)
Staphylococcus aureus 10 3 13 (23)
a-Hemolytic streptococci 3 2 5 (8)
Enterococcus spp. 3 2 5 (8)
Gram-positive bacilli 5 0 5 (8)
Streptococcus pneumonae 2 0 2 (3)
Gram-negative 40 19 59
Pseudomonas aeruginosa 12 1 13 (22)
Klebsiella spp 8 3 11 (19)
Escherichia coli 9 1 10 (17)
Enterobacter spp 5 2 7 (12)
Acinetobacter spp 3 3 6 (11)
Burkholderia cepacia 1 1 2 (3)
Serratia spp 1 1 2 (3)
Citrobacter freundii 1 1 2 (3)
Stenotrophomonas maltophilia 0 2 2 (3)
Non-fermentating bacilli 0 2 2 (3)
Haemophilus inﬂuenzae 0 1 1 (2)
Alacligenes spp 0 1 1 (2)
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(OR 10.02, 95% CI 2.64–38.03) were associated with
infection due to MDR Gram-negative isolates.
Outcome and predictors of death
Forty patients died during the neutropenic phase after
HSCT (10%). Twenty-ﬁve (62%) of these 40 patients
developed an infection that was attributed by the investi-
gators as the cause of death. The death rate of patients with
bacteremia due to MDR Gram-negative isolates was 20%
(four of 20 patients), compared to 9% in the rest of the
cohort (P¼ 0.12). The MDR Gram-negative bacteria
recovered from the blood of the four patients who died
were E. coli (2 cases), K. pneumoniae and P. aeruginosa. No
MDR Gram-negative isolate was susceptible to the initial
empiric antibiotic regimen given by the time the isolates
were recovered. Univariate predictors of death were:
second HSCT (death rates 33 vs 9%, P¼ 0.01), underlying
disease other than CML (12 vs 1%, P¼ 0.006), documen-
tation of infection (14 vs 4%, P¼ 0.001), bacteremia (18 vs
7%, P¼ 0.003), bacteremia due to S. aureus (31 vs 9%,
P¼ 0.03), bacteremia due to E. coli (40 vs 9%, P¼ 0.01),
and persistent bacteremia (36 vs 9%, P¼ 0.02). By multi-
variate analysis, factors associated with death were second
HSCT (OR 3.55, 95% CI 1.11–12.50, P¼ 0.03), underlying
disease other than CML (OR 8.38, 95% CI 1.13–62.42,
P¼ 0.04), documentation of infection (OR 3.27, 95% CI
1.30–8.23, P¼ 0.01) and bacteremia due to E. coli
(OR 4.17, 95% CI 1.09–16.67, P¼ 0.04).
Discussion
Our study was the ﬁrst collaborative effort involving
different Brazilian institutions designed to collect prospec-
tive data on bacteremia among HSCT recipients. The
participating transplant centers were selected among about
40 centers in Brazil, to target representative information on
the epidemiology of these infections in different regions of
Brazil. We used a web-based case-report form to facilitate
the processes of entering data, generating queries and
analyzing. The system enabled us to have immediate access
to every case entered in the database, and to analyze all
data once the database was cleared. We observed a 5%
Table 3 Susceptibility pattern of the Gram-negative bacterial isolates
Bacteria (n) AMK CAZ FEP TZP CIP IMP ESBL
S R NT S R NT S R NT S R NT S R NT S R NT
Multi-drug-resistant isolates (22)
K. pneumoniae (7) 2 5 0 0 7 0 1 6 0 1 5 1 0 6 1 6 0 1 6
P. aeruginosa (5) 1 4 0 0 5 0 0 5 0 1 4 0 1 4 0 1 4 0 0
Enterobacter sp. (3) 2 1 0 0 3 0 2 1 0 0 0 3 1 2 0 3 0 0 0
E. coli (2) 2 0 0 0 2 0 0 2 0 1 0 1 2 0 0 2 0 0 2
B. cepacia (1) 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0
S. malthophilia (2) 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0
Acinetobacter sp. (1) 0 1 0 0 1 0 0 1 0 0 1 0 1 0 0 0 1 0 0
Citrobacter freundii (1) 0 1 0 0 1 0 0 1 0 0 0 1 0 0 1 1 0 0 0
Non-multi-drug-resistant isolates (37)
P. aeruginosa (8) 8 0 0 8 0 0 8 0 0 8 0 0 7 1 0 7 0 1 0
E. coli (8) 6 1 1 6 0 2 6 2 0 8 0 0 8 0 0 8 0 0 0
Acinetobacter sp. (5) 4 0 1 4 0 1 3 1 1 4 0 1 4 0 1 4 0 1 0
Enterobacter sp. (4) 3 0 1 2 1 1 3 0 1 3 0 1 2 1 1 3 0 1 0
K. pneumoniae (4) 3 0 1 3 0 1 3 0 1 3 0 1 3 0 1 2 0 2 0
Non-fermentative Gram-negative bacilli (3) 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 0
Serratia marcescens (2) 1 0 1 1 0 1 1 0 1 1 0 1 1 0 1 1 0 1 0
Citrobacter freundii (1) 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0
Haemophilus sp. (1) 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 0
Alcaligenes xyloxidans (1) 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0
Abbreviations: AMK¼ amikacin; CAZ¼ ceftazidime; CIP¼ ciproﬂoxacin; ESBL¼ extended-spectrum betalactamase; FEP¼ cefepime; IMP¼ imipenem;
NT¼ not tested; R¼ resistant; S¼ sensitive; TZP¼piperacillin-tazobactam.
Table 4 Univariate and multivariate predictors of bacteremia due to multi-drug-resistant Gram-negative isolates
Variablea Univariate Multivariate
OR (95% CI) P-value OR (95% CI) P-value
Receipt of third-generation cephalosporins 7.48 (2.85–19.60) o0.001 10.65 (3.75–30.27) o0.001
Hospital A 5.18 (1.57–17.10) 0.02 9.47 (2.60–34.40) 0.001
Hospital B 4.16 (1.41–12.30) 0.02 3.67 (0.73–18.43) 0.15
Hospital C 0.13 (0.02–0.98) 0.02 0.31 (0.04–2.54) 0.27
aVariables analyzed: gender, age, institution, underlying disease, type of transplant, source of stem cells, antibacterial and antifungal prophylaxis, venous
access, exposure to third- or fourth-generation cephalosporins, carbapenems, vancomycin, penicillin, anti-anaerobes and quinolones.
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overall incidence of bacteremia caused by MDR Gram-
negative isolates, and identiﬁed two variables associated
with this infection: receipt of third-generation cephalospor-
ins and being at one of the 13 centers.
In European and North-American series, Gram-positive
bacteria contribute to the majority of bacteremias during
febrile neutropenia,3,15,16 but recent studies have suggested
that the incidence of Gram-negative bacteremia is increas-
ing.1,2,17 A recent review from sequential EORTC trials of
antibiotics in febrile neutropenia reported a resurgence of
Gram-negative bacteremia, and in the period from 1993 to
2000, the incidence of Gram-negative and Gram-positive
infections were approximately the same (12 and 13%,
respectively).5 In Brazil, a recently published single-center
study showed that Gram-negative bacteria accounted for
51.9% of bloodstream infections in neutropenic cancer
patients.18 On the other hand, another study showed that
Gram-positive bacteria accounted for 56% of 23 episodes
of bacteremia among 68 febrile neutropenic children
enrolled in a clinical trial.19 Among HSCT recipients, data
from a single center showed a predominance of Gram-
positive bacteria (64% of 36 episodes of bacteremia among
120 autologous HSCT recipients).20 In the present study,
Gram-positive bacteria accounted for 47% of episodes of
bacteremia, whereas 37% were caused by Gram-negative
bacteria, and 16% were mixed infections, but the number
of bloodstream isolates was equal (59 isolates each).
Despite the paucity of data, taken together these data
suggest that the frequency of Gram-negative bacteremia is
higher in Brazilian series compared to North American and
European series. Although the reasons for these observa-
tions are not very clear, one possibility is that only 13% of
our HSCT recipients received quinolone prophylaxis. The
use of quinolones reduces Gram-negative bacteremia,21 and
has been regarded as one of the main reasons for the
decrease in Gram-negative bacteremia among neutropenic
patients observed in the northern hemisphere in the 1990s.
However, some authors reported an increase in Gram-
negative bacteremia despite use of quinolone prophylaxis.22
The use of quinolone prophylaxis in the present study
reduced by 85% the risk of developing fever. The other
variable associated with a reduction in the risk of
developing fever during the neutropenia was non-myelo-
ablative HSCT. This type of transplant is typically
associated with less-severe neutropenia and mucositis
compared with myeloablative transplants.23
As reported in most series, coagulase-negative staphylo-
cocci accounted for the majority of Gram-positive isolates
(24% of the 118 bloodstream isolates and 49% of Gram-
positive isolates), although in lower proportion than that
reported elsewhere.3,17,24 Of note, S. aureus was the second
most frequent agent of bacteremia (13 isolates, 23% of
Gram-positive isolates and 11% of all bloodstream
isolates), together with P. aeruginosa. This is in contrast
to the low frequency of this agent in bloodstream infections
of neutropenic patients from Europe and North America.1–3
Interestingly, in another study at a Brazilian cancer center,
S. aureus accounted for 12% of bloodstream isolates
among neutropenic patients.18
Among Gram-negative bacteria, P. aeruginosa, K.
pneumoniae and E. coli were the most frequent agents of
bacteremia. The susceptibility proﬁle of Gram-negative
isolates showed a signiﬁcant proportion of MDR, accord-
ing to our deﬁnition: 37% of Gram-negative bloodstream
isolates were MDR. Drug resistance has become a great
concern among patients with hematologic malignancies.
Lang et al.25 reported a greater proportion of resistant
isolates in hematologic ward compared to the intensive care
unit, and attributed it to a high density of antimicrobial use
among hematologic patients. In our study, resistance was
most frequently observed with K. pneumoniae (six out of 11
isolates), Enterobacter sp (three out of seven isolates), P.
aeruginosa (ﬁve out of 13 isolates), and E. coli (two out of
10 isolates). These four agents accounted for 72% of MDR
Gram-negative isolates. Among enterobacteria, the rates of
extended-spectrum b-lactamases (ESBL) production were
high (four of 11K. pneumoniae and two of 10 E. coli), as
was the rate of resistance of P. aeruginosa to third-
generation cephalosporins and carbapenems. This is in
contrast with another study in HSCT recipients,1 in which
enterobacteria remained fully sensitive to most antimicro-
bial agents, and only 14% of P. aeruginosa isolates were
resistant to ceftazidime and tobramicin. Conversely, Lang
et al.25 reported that 39, 74 and 88% of P. aeruginosa
isolates were resistant to cefepime, imipenem and cipro-
ﬂoxacin, respectively.
In the present study, previous exposure to third-
generation cephalosporins and belonging to one of the
HSCT centers were associated with an increased risk for
MDR Gram-negative bacteremia by multivariate analysis.
The use of antimicrobials has been found to be related with
acquisition of multi-resistant pathogens in similar studies.
Spanik et al.26 reported a higher incidence of MDR Gram-
negative infections in neutropenic cancer patients who
received third-generation cephalosporins as prophylaxis
(41.2 vs 13.7%, Po0.01). The authors also reported that
previous use of quinolones and other broad-spectrum
antibiotics (second generation cephalosporins, aminoglyco-
sides and imipenem) were more frequently associated with
MDR Gram-negative infections. The use of quinolones has
also been identiﬁed as a risk factor for P. aeruginosa-
producing metallobetalactamase in a tertiary-care hospital
in Brazil.27 In the present study, we observed a trend to a
higher incidence of infection due to MDR Gram-negative
isolates in patients who received quinolone prophylaxis
(14 vs 5%, P¼ 0.07). By contrast, the use of third-
generation cephalosporins was strongly associated with
bacteremia owing to MDR Gram-negative isolates. This is
not surprising, since most of our MDR Gram-negative
isolates were enterobacteria-producing ESBL, a mechanism
of resistance that may be induced by the exposure to this
class of antibiotics.28–30
The other risk factor for MDR Gram-negative bacter-
emia found in the present study was being at a speciﬁc
HSCT center. Interestingly, in that particular center no
patient was exposed to third-generation cephalosporins.
These ﬁndings suggest the local epidemiology in the whole
hospital may strongly inﬂuence the rates of resistance at a
particular HSCT unit.
We did not observe an association between infection
owing to MDR Gram-negative bacteria and death. Con-
versely, having an underlying disease other than CML and
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undergoing a second transplant were strongly associated
with a higher death rate by multivariate analysis. Both
factors are expected to impact negatively on the immunity
to increasing the risk for infection as well as organ
toxicity.31
This study has some limitations. Its main objective was
to evaluate the epidemiology of bacteremia in the
neutropenic phase of HSCT recipients in Brazil. To have
a large number of centers that were representative of
different regions, we designed a case report form with a
limited number of variables. Therefore, some potential risk
factors for MDR Gram-negative infection were not
available, such as past history of hospitalization, use of
antibiotics, as well as a proﬁle of the rates of resistance in
each hospital. Likewise, since we did not get information
regarding changes in the empiric antibiotic regimen, we
could not evaluate the impact of the use of appropriate
antibiotic coverage and the outcome of MDR Gram-
negative bacteremia. Furthermore, since we did not ask the
investigators to send the isolates recovered from the blood
cultures, we did not explore the possibility of clonality
among the MDR Gram-negative isolates.
In conclusion, we observed a high rate of Gram-negative
bacteremia among HSCT recipients from Brazil, and 37%
of these isolates were MDR. Receipt of third-generation
cephalosporins and being at one of the 12 centers were risk
factors for the occurrence of these infections. These ﬁndings
may have important clinical implications in decisions
relating to prophylaxis and selection of the most appro-
priate regimen for empiric antibiotic treatment. Continuous
surveillance is needed, especially in the centers with high
incidences of resistance.
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